Virtu KCG Holdings’s Tempest Therapeutics TPST Stock Holding History

Virtu KCG Holdings’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$117K	Sell	26 -43	-62%	-$182K	﹤0.01%	2373
2017 Q1	$375K	Buy	+69	New	+$321K	0.01%	1689
2016 Q3	–	Sell	-5	Closed	-$81K	–	3468
2016 Q2	$81K	Buy	+5	New	+$114K	﹤0.01%	2586
2015 Q4	–	Sell	-4	Closed	-$108K	–	3936
2015 Q3	$108K	Sell	4 -2	-33%	-$135K	﹤0.01%	2808
2015 Q2	$478K	Buy	+6	New	+$550K	0.01%	1534

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtu KCG Holdings's TPST Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Tempest Therapeutics (TPST) stake by 62% in Q2 2017, selling an estimated $182K and leaving 26 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #2373.

Virtu KCG Holdings first reported a position in TPST in Q2 2015 and has held it in 5 quarters since. The position peaked at $478K in Q2 2015. 54 funds tracked by Wall St. Rank hold TPST as of Q2 2017.

Virtu KCG Holdings held 26 shares of Tempest Therapeutics worth $117K as of Q2 2017.
Virtu KCG Holdings sold 43 Tempest Therapeutics shares in Q2 2017, an estimated $182K.
Tempest Therapeutics made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2373 holding.
Virtu KCG Holdings first reported a position in Tempest Therapeutics in Q2 2015 and has held it in 5 quarters since.
Virtu KCG Holdings's Tempest Therapeutics position peaked at $478K in Q2 2015.
54 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.